Related Experiment Video
Updated: Dec 17, 2025
07:43
Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
Published on: May 3, 2024
4.1K
Identification of the Novel Target Genes for Osteosarcoma Therapy Based on Comprehensive Bioinformatic Analysis
Xi Zhou1, Yu Fan1, Weiliang Ye2
1Department of Orthopaedic Surgery, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China.
DNA and Cell Biology
|June 26, 2020
Summary
This study identifies three key genes, miR-29c, BVES, and PSMB2, as potential therapeutic targets for osteosarcoma. High miR-29c and BVES indicate better prognosis, while high PSMB2 suggests a poor outcome in bone cancer patients.
Area of Science:
- Oncology
- Bioinformatics
- Molecular Biology
Background:
- Osteosarcoma is a common bone cancer, primarily affecting teenagers.
- Current treatments for osteosarcoma require improvement, necessitating new therapeutic strategies.
Purpose of the Study:
- To identify key genes, molecules, and pathways crucial for osteosarcoma survival using bioinformatic analysis.
- To discover novel therapeutic targets for osteosarcoma prevention and treatment.
Main Methods:
- Downloaded and analyzed four Gene Expression Omnibus (GEO) microarray datasets (GSE99671, GSE87624, GSE65071, GSE28423) of human bone and osteosarcoma samples.
- Identified differentially expressed messenger RNAs (mRNAs) and microRNAs (miRNAs).
- Utilized bioinformatics tools to analyze Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, miRNA-mRNA interactions, gene-disease relationships, and overall survival.
Main Results:
- Identified three critical genes: miR-29c, blood vessel epicardial substance (BVES), and proteasome 20S subunit beta 2 (PSMB2).
- Observed high expression of BVES and PSMB2, and low expression of miR-29c in osteosarcoma tissues.
- Found that high miR-29c and BVES expression correlate with better prognosis, while high PSMB2 expression correlates with poor prognosis.
- Suggested a potential regulatory relationship where PSMB2 may be a target of miR-29c.
Conclusions:
- The identified differentially expressed genes and miRNAs offer insights into osteosarcoma's molecular mechanisms.
- miR-29c, BVES, and PSMB2 represent potential novel therapeutic targets for osteosarcoma diagnosis and treatment.
- Further investigation into the miR-29c/PSMB2 axis could reveal new therapeutic avenues for osteosarcoma.
